Sartorius Stedim Biotech (OTCMKTS:SDMHF) Trading 3.2% Higher – Here’s Why

Sartorius Stedim Biotech S.A. (OTCMKTS:SDMHF)’s stock price shot up 3.2% on Thursday . The company traded as high as $196.50 and last traded at $196.00. 175 shares changed hands during trading, a decline of 95% from the average session volume of 3,274 shares. The stock had previously closed at $190.00.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group downgraded shares of Sartorius Stedim Biotech from a “buy” rating to a “neutral” rating in a research note on Monday, January 12th. One analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold”.

Sartorius Stedim Biotech Stock Up 3.2%

The stock’s 50 day moving average price is $198.69 and its 200 day moving average price is $222.21.

Sartorius Stedim Biotech Company Profile

Sartorius Stedim Biotech SA (OTCMKTS: SDMHF) is a global provider of bioprocessing equipment and services for the biopharmaceutical industry. The company develops and manufactures technologies that support the development and production of vaccines, monoclonal antibodies, therapeutic proteins and cell‐ and gene‐based therapies. Its solutions address both upstream processes—such as cell cultivation and fermentation—and downstream processes, including filtration, centrifugation and chromatography.

Key product offerings include single‐use bioreactors and mixers, modular filtration assemblies, prepacked chromatography columns, and a wide range of cell culture media and buffer systems.